Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.70 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.67 |
| ▸ | ABAT | P80404 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 7/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256312 | 0.89 | ALDH5A1 (0.80) | AKT1ALDH5A1ABATTSHRTP53 | |
| Biphenyl SCHEMBL5090009 | 0.89 | AKT1 (0.69) | AKT1ALDH5A1ABATTSHRTP53 | |
| Terephthalic Acid SCHEMBL8211964 | 0.84 | TSHR (0.67) | AKT1TSHRTP53SRD5A2ALDH1A1 | |
| Terephthalic Acid SCHEMBL28022775 | 0.84 | TSHR (0.67) | AKT1TSHRTP53SRD5A2ALDH1A1 | |
| SCHEMBL8835740 | 0.83 | ALDH5A1 (0.64) | AKT1ALDH5A1ABATTSHRTP53 | |
| SCHEMBL10772833 | 0.82 | ALDH5A1 (0.70) | AKT1ALDH5A1ABATTP53THRB | |
| SCHEMBL38134 | 0.82 | AKT1 (1.00) | AKT1ALDH5A1ABATTSHRTP53 | |
| Benzene SCHEMBL27516217 | 0.82 | AKT1 (1.00) | AKT1ALDH5A1ABATTSHRTP53 | |
| SCHEMBL4315033 | 0.82 | ALDH5A1 (0.70) | AKT1ALDH5A1ABATTP53THRB | |
| Terephthalic Acid SCHEMBL15799684 | 0.82 | TSHR (0.63) | AKT1TSHRTP53SRD5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115068348-A | Curable composition for dental use having excellent storage stability | 株式会社松风 | 2022-09-20 | — | — | CN | disclosed |
| CN-115068347-A | Photocurable composition having excellent depth of cure | 株式会社松风 | 2022-09-20 | — | — | CN | disclosed |
| CN-115068346-A | Dental photocurable composition having excellent handling properties and storage stability | 株式会社松风 | 2022-09-20 | — | — | CN | disclosed |
| CN-113402666-A | Dental photocurable composition with excellent color tone selectivity | 株式会社松风 | 2021-09-17 | — | — | CN | disclosed |
| CN-113402665-A | Dental photocurable composition comprising highly soluble photoacid generator | 株式会社松风 | 2021-09-17 | — | — | CN | disclosed |
| WO-2016097626-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
| US-7396486-B2 | Polymerizable mixtures | WACKER CHEMIE AG (DE) | 2008-07-08 | — | — | US | disclosed |
| CN-1302089-C | Polymerisable mixtures | CONSORTIUM ELEKTROCHEM IND (DE) | 2007-02-28 | — | — | CN | disclosed |
| EP-1740556-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060097224-A1 | Polymerisable mixtures | WACKER CHEMIE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| CN-1711335-A | Polymerisable mixtures | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-21 | — | — | CN | disclosed |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097760-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-0073456-B1 | TETRAAZAANNULENE COBALT COMPLEX COMPOUNDS AND METHOD FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | HAVCR2, HCCS, AADAC | AKT1 1425/4885ALDH5A1 948/4885ABAT 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.